Literature DB >> 10713355

Characterisation of autoantibodies to peripheral myelin protein 22 in patients with hereditary and acquired neuropathies.

M F Ritz1, J Lechner-Scott, R J Scott, P Fuhr, N Malik, B Erne, V Taylor, U Suter, N Schaeren-Wiemers, A J Steck.   

Abstract

To investigate the possibility that an autoimmune mechanism may play a role in the hereditary neuropathy Charcot-Marie-Tooth type 1A (CMT1A), sera were analysed by Western blot for anti-peripheral myelin protein 22 (PMP22) autoantibodies. These sera were compared with sera from patients with CMT type 2 (CMT2), acquired peripheral neuropathies such as chronic inflammatory demyelinating neuropathy (CIDP), anti-MAG IgM neuropathy, Miller-Fisher syndrome (MFS), diabetic neuropathy and with control blood donors. Anti-PMP22 positive sera were detected in 70% of patients with CMT1 and unexpectedly in 60% of patients with CMT2. Interestingly, 44% of the patients with other peripheral neuropathies and 23% of the apparently healthy controls showed also anti-PMP22 antibody reactivity. Immunohistochemical analysis of the human anti-PMP22 antisera on healthy sural nerve sections and on PMP22-expressing COS cells revealed that these sera did not recognise endogenous PMP22. Our results indicate that anti-PMP22 autoantibodies are found in sera of patients with different types of peripheral neuropathies, but their role in the pathogenesis of these diseases remains to be determined.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10713355     DOI: 10.1016/s0165-5728(99)00250-7

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  8 in total

Review 1.  Management of chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Richard A C Hughes
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications.

Authors:  Luis Querol; Jérôme Devaux; Ricard Rojas-Garcia; Isabel Illa
Journal:  Nat Rev Neurol       Date:  2017-07-14       Impact factor: 42.937

3.  T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  P A Csurhes; A-A Sullivan; K Green; M P Pender; P A McCombe
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-10       Impact factor: 10.154

4.  Immunological study of hereditary motor and sensory neuropathy type 1a (HMSN1a).

Authors:  C M Gabriel; N A Gregson; N W Wood; R A C Hughes
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-02       Impact factor: 10.154

5.  Clinical disease severity and axonal dysfunction in hereditary motor and sensory neuropathy Ia.

Authors:  Camiel Verhamme; Ivo N van Schaik; Johannes H T M Koelman; Rob J de Haan; Marinus Vermeulen; Marianne de Visser
Journal:  J Neurol       Date:  2004-12       Impact factor: 4.849

6.  Serum IgG antibodies to P0 dimer and 35 kDa P0 related protein in neuropathy associated with monoclonal gammopathy.

Authors:  A Favereaux; A Lagueny; A Vital; J-M Schmitter; S Chaignepain; X Ferrer; I Labatut-Cazabat; C Vital; K G Petry
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-09       Impact factor: 10.154

7.  Genetically determined neuropathy (CMT 1A) accompanied by immune dysfunction: a case report.

Authors:  Zsuzsanna Pál; E Kiss; A Gál; T Csépány; A Lengyel; Maria Judit Molnar
Journal:  Inflamm Res       Date:  2009-03-10       Impact factor: 4.575

Review 8.  Chronic inflammatory demyelinating polyradiculoneuropathy: from pathology to phenotype.

Authors:  Emily K Mathey; Susanna B Park; Richard A C Hughes; John D Pollard; Patricia J Armati; Michael H Barnett; Bruce V Taylor; P James B Dyck; Matthew C Kiernan; Cindy S-Y Lin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2015-02-12       Impact factor: 10.154

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.